Lucas C. Zarling
YOU?
Author Swipe
View article: Subclonal response heterogeneity to define cancer organoid therapeutic sensitivity
Subclonal response heterogeneity to define cancer organoid therapeutic sensitivity Open
Tumor heterogeneity is predicted to confer inferior clinical outcomes with precision-based strategies, however, modeling heterogeneity in a manner that still represents the tumor of origin remains a formidable challenge. Sequencing technol…
View article: Issue Information
Issue Information Open
Outpatient consolidation chemotherapy with intermediate dose cytarabine has similar survival and relapses rates in acute myeloid leukemia as compared
View article: Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia
Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia Open
Treatments for adults with newly-diagnosed acute lymphoblastic leukemia (ALL) may be prohibitively toxic and/or resource-intense. To address this, we performed a phase II study of dose-adjusted etoposide, prednisone, vincristine, cyclophos…
View article: Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation
Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation Open
Not available.
View article: Utility of the Treatment-Related Mortality (TRM) score to predict outcomes of adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation
Utility of the Treatment-Related Mortality (TRM) score to predict outcomes of adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation Open
View article: Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML
Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML Open
In acute myeloid leukemia (AML), measurable residual disease (MRD) before or after allogeneic hematopoietic cell transplantation (HCT) is an established independent indicator of poor outcome. To address how peri-HCT MRD dynamics could refi…
View article: Integrating Subclonal Response Heterogeneity to Define Cancer Organoid Therapeutic Sensitivity
Integrating Subclonal Response Heterogeneity to Define Cancer Organoid Therapeutic Sensitivity Open
Tumor heterogeneity is predicted to confer inferior clinical outcomes, however modeling heterogeneity in a manner that still represents the tumor of origin remains a formidable challenge. Sequencing technologies are limited in their abilit…
View article: Polycystic Liver Disease in a Patient With Metastatic Renal Cell Carcinoma: A Case Report
Polycystic Liver Disease in a Patient With Metastatic Renal Cell Carcinoma: A Case Report Open
We report a case of rapid evolution of polycystic liver disease in a 76-year-old patient with metastatic renal cell carcinoma who underwent treatment with numerous antineoplastic agents. The aim was to identify a causative etiology for the…
View article: Recognition of microbial glycans by human intelectin-1
Recognition of microbial glycans by human intelectin-1 Open